Clinical trials: Autotransplantation
Multiple Myeloma, Lymphoma, Non-Hodgkin's
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
This Phase 2 study was designed to assess the safety and hematological activity of AMD3100 (plerixafor) in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) who were predicted to be unable to mobilize ≥2*10^6…
- Trial name
- NCT00395967
- Testing
- G-CSF plus plerixafor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Genzyme, a Sanofi Company
Burns
Assessment of Safety and Effectiveness of Biodegradable Temporizing Matrix in the Treatment of Deep Burn Skin Injuries
This is a multi-center, single arm, traditional feasibility study to allow a preliminary assessment of the safety and effectiveness of a new method of treating skin burns using Biodegradable Temporizing Matrix (BTM).
- Trial name
- NCT02905435
- Testing
- Biodegradable Temporizing Matrix
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- PolyNovo Biomaterials Pty Ltd.
Full Thickness Thermal Burn
StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns
Autografting is a surgical procedure to transplant healthy skin (donor skin) from another part of the participant's own body (donor site) to the burned part. Autografting is the usual treatment for full-thickness (FT) burns.
- Trial name
- StrataSOMA (NCT04765202)
- Testing
- AG Tx, SOMA Tx
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Stratatech, a Mallinckrodt Company
Multiple Myeloma
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
The purpose of this Phase 2 randomized study is to evaluate the efficacy and safety of treatment with a regimen of VELCADE, dexamethasone, and thalidomide (VDT) or VELCADE, dexamethasone, thalidomide, and cyclophosphamide (VDTC)…
- Trial name
- NCT00531453
- Testing
- bortezomib, dexamethasone, and thalidomide, bortezomib, dexamethasone, thalidomide, and cyclophosphamide
- Where
- Austria
- Volunteers
- 98 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Burns
Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
The primary objective is to compare the effectiveness of treatment with Sulfamylon® solution as the initial topical moist dressing over meshed autografts following the initial graft procedure on preventing graft loss in a…
- Trial name
- NCT00634166
- Testing
- Sulfamylon® For 5 % Topical Solution, Topical Antimicrobial/Antifungal Medications
- Where
- 9 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mylan Inc.
Multiple Myeloma
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
- Trial name
- GENESIS (NCT03246529)
- Testing
- BL-8040 1.25 mg/kg + G-CSF
- Where
- 18 sites in United States, Germany and 3 more
- Volunteers
- 180 people
- Sponsor
- BioLineRx, Ltd.
Burn, Thermal
StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements
About 70 participants will be enrolled. They will have complex skin defects because of burns caused by heat. The burns will: be on 3-49% of the participant's total body surface area (TBSA) require surgery for skin replacement…
- Trial name
- NCT03005106
- Testing
- StrataGraft Skin Tissue, Autograft
- Where
- 16 sites in United States
- Volunteers
- 71 people
- Sponsor
- Stratatech, a Mallinckrodt Company
Skin Wound, Burns
StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
The proposed study is designed as a phase Ib open-label, dose-escalation, multicenter study evaluating the safety, tolerability, and efficacy of StrataGraft skin tissue in promoting the healing of the deep partial-thickness…
- Conditions
- Skin Wound, Burns, Trauma-related Wound
- Trial name
- NCT01437852
- Testing
- StrataGraft Skin Tissue
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Stratatech, a Mallinckrodt Company
Lymphoma, Non-Hodgkin
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF alone to mobilize and collect the optimal…
- Trial name
- NCT00103610
- Testing
- Granulocyte colony-stimulating factor plus plerixafor
- Where
- 32 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Genzyme, a Sanofi Company
Trauma-related Wound, Burns
StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects
About 20 participants will be enrolled in this trial if they have had an accident that damages both the dermal (outside) and epidermal (inside) layers of skin on up to 49% of their body.
- Conditions
- Trauma-related Wound, Burns, Skin Wound
- Trial name
- NCT03005054
- Testing
- StrataGraft Skin Tissue, Autograft
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Stratatech, a Mallinckrodt Company
Lymphoma, Large-Cell, Diffuse
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant
- Trial name
- NCT00622388
- Testing
- Ofatumumab
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the…
- Trial name
- NCT00103662
- Testing
- Granulocyte colony-stimulating factor plus plerixafor
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 302 people
- Sponsor
- Genzyme, a Sanofi Company
Autologous Stem Cell Transplantation
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous…
- Trial name
- NCT00396331
- Testing
- G-CSF plus plerixafor
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genzyme, a Sanofi Company
Deep Partial-thickness Burn
StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )
An autograft is a piece of skin taken from a healthy area of the body to be used to treat severe burns on another part of the same body.
- Trial name
- NCT04123548
- Testing
- StrataGraft skin tissue
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- Stratatech, a Mallinckrodt Company
Tibial Delayed Healing
Tibial Delayed Healing Pivotal Clinical Trial
Evaluate the INFUSE/MASTERGRAFT™ Delayed Healing Device as an alternative/replacement to autograft in the treatment of tibial delayed healing.
- Trial name
- NCT01016067
- Testing
- INFUSE/MASTERGRAFT, Autograft bone
- Where
- 16 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Medtronic Spinal and Biologics
Non-Hodgkin Lymphoma, Hodgkin Disease
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)
Participants with non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD) will be assigned to one of 2 arms based on the immunophenotype of their lymphoma.
- Trial name
- NCT00444912
- Testing
- G-CSF plus plerixafor, rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma, Lymphoma, Non-Hodgkin
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with…
- Trial name
- NCT00396266
- Testing
- G-CSF Plus Plerixafor
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
Knee Injury
Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site From an Autograft in the Knee.
The main objective of this study is to test the ability of an allograft plug to provide a successful repair of an osteochondral defect left at the harvest site during OATS procedure.
- Trial name
- CRB (NCT00821873)
- Testing
- CR Plug
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- RTI Surgical
Full-thickness Skin Defects, Degloving Injuries
RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
A prospective randomized within-subject controlled study to compare the clinical performance of conventional autografting with and without the RECELL system on acute non-burn full-thickness skin defects.
- Conditions
- Full-thickness Skin Defects, Degloving Injuries, Crush Injuries, Laceration of Skin
- Trial name
- NCT04091672
- Testing
- Control Intervention (Conventional Autograft), Investigational Intervention (RECELL + more widely meshed autograft)
- Where
- 18 sites in United States
- Volunteers
- 65 people
- Sponsor
- Avita Medical
Multiple Myeloma
PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
To assess and compare the pharmacokinetics of Melphalan HCL for Injection (Propylene Glycol-Free) versus Alkeran for Injection in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).
- Trial name
- NCT00925782
- Testing
- Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection, Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Acrotech Biopharma Inc.